Mayo Clinic | Strategic Alliance Partners

Rafael Fonseca, MD, hematologist, Mayo Clinic, discusses the use of fluorescence in situ hybridization (FISH) in diagnosing patients with myeloma.

Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the role of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia.

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses traditional imaging modalities and newer counterparts that are used to detect prostate cancer.

Alan H. Bryce, MD, discusses emerging agents and next steps in the treatment of patients with in nonmetastatic prostate cancer.

Mark Tyson, MD, discusses the management of localized advanced bladder cancer, the promise of immunotherapy, and his advice for urologists treating patients with bladder cancer.

Erik P. Castle, MD, discusses the importance of risk stratifying low- and intermediate-risk localized prostate cancers.

Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.

Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses the use of adjuvant versus early salvage therapy in patients with prostate cancer, citing his own preference for early salvage therapy.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses genetic abnormalities in multiple myeloma.

Mark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.

Patients with peripheral T-cell lymphoma are more likely to have superior overall survival if they have previously demonstrated event-free survival at 24 months.

Steven R. Alberts, MD, discusses current advancements being made for patients with advanced liver cancer.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the desire to use biological heterogeneity as a factor for treatment in newly diagnosed patients with mantle cell lymphoma (MCL).

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

Tanios Bekaii-Saab, MD, discusses the promise of napabucasin in pancreatic cancer.

Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.